ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alisertib

Also written as “Alisertib”, “[^14C]-alisertib” and “Alisertib (MLN8237)”.

Its studies are mostly in Lymphoma · Small Cell Lung Carcinoma · Breast Neoplasms · Ovarian Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Drug pageMLN 8237: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 28, 201124 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda200 open or runningphase 3since Nov 28, 2011Jul 12, 2007none ahead
Puma Biotechnologyits history only33 open or runningphase 2since Sep 27, 2023Sep 27, 2023Oct 30, 2027phase 2 · NCT06095505
Sarah Cannon Research Instituteits history only10 open or runningphase 2since Jul 6, 2014Jul 6, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Jul 12, 2007.

  1. Aug 18, 2009Phase 1 study in Advanced Solid TumorsNCT00962091 · 53 enrolled · United States
  2. Jan 8, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01045421 · 273 enrolled · United States
  3. Mar 17, 2010Phase 1 study in Advanced Solid TumorsNCT01094288 · 41 enrolled · United States
  4. Jul 17, 2011Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT01397825 · 45 enrolled · United States, Italy, Spain and more
  5. Nov 28, 2011Phase 3 study in Lymphoma, T-Cell, PeripheralNCT01482962 · 271 enrolled · United States, Australia, Austria and more
  6. Jan 13, 2012Phase 1 study in LymphomaNCT01512758 · 36 enrolled · Singapore
  7. Jun 1, 2012Phase 1 study in Advanced Nonhematologic MalignanciesNCT01613261 · United States
  8. Oct 17, 2012Phase 1 study in LymphomaNCT01714947 · 3 enrolled · United States
  9. Apr 29, 2013Phase 1 study in LymphomaNCT01844583 · 55 enrolled · United States
  10. Jul 1, 2013Phase 1 study in LymphomaNCT01898078 · 26 enrolled · United States
  11. Dec 4, 2013Phase 2 study in Small Cell Lung CarcinomaNCT02038647 · 178 enrolled · United States, Belgium, Canada and more
  12. Jul 30, 2014Phase 1 study in LymphomaNCT02214147 · 36 enrolled · United States
  13. Oct 3, 2014Phase 1 study in LymphomaNCT02259010 · 24 enrolled · United States
  14. Feb 11, 2015Phase 1 study in Ovarian NeoplasmsNCT02367352 · 9 enrolled · Japan, Korea, Republic of

TargetBeta

AURKA →read by rule
“Serine/threonine-protein kinase Aurora-A inhibitor”ChEMBL 37, by rule

Studies

All 20 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02367352Ovarian Neoplasms · Japan, Korea, Republic of1TerminatedMay 23, 20179
NCT02259010Lymphoma · United States1CompletedMar 27, 201524
NCT02214147Lymphoma · United States1CompletedApr 5, 201636
NCT02038647Small Cell Lung Carcinoma · United States, Belgium, Canada and more2CompletedJan 3, 2016178
NCT01898078Lymphoma · United States1CompletedMar 5, 201426
NCT01844583Lymphoma · United States1CompletedAug 4, 201455
NCT01714947Lymphoma · United States1CompletedApr 4, 20133
NCT01613261Advanced Nonhematologic Malignancies · United States1WithdrawnSep 20150
NCT01512758Lymphoma · Singapore1CompletedOct 8, 201336
NCT01482962Lymphoma, T-Cell, Peripheral · United States, Australia, Austria and more3CompletedJun 30, 2015271
NCT01397825Lymphoma, Large B-Cell, Diffuse · United States, Italy, Spain and more2CompletedFeb 5, 201545
NCT01094288Advanced Solid Tumors · United States1CompletedFeb 28, 201441
NCT01045421Carcinoma, Non-Small-Cell Lung · United States2CompletedMay 2013273
NCT00962091Advanced Solid Tumors · United States1CompletedDec 28, 201153
NCT00853307Ovarian Neoplasms · United States2CompletedNov 23, 200931
NCT00830518Leukemia, Myeloid, Acute · United States2CompletedFeb 2, 201057
NCT00807495Lymphoma, Large B-Cell, Diffuse · United States2CompletedJan 4, 201148
NCT00697346Lymphoma, B-Cell, Marginal Zone · United States1CompletedOct 1, 201658
NCT00651664Advanced Malignancies · Spain1CompletedSep 1, 201059
NCT00500903Advanced Malignancies · United States1CompletedAug 1, 201087

How it is read

Names in the registry

  • “Alisertib”, 23 entries
  • “alisertib”, 2 entries
  • “[^14C]-alisertib”, 1 entry
  • “Alisertib (MLN8237)”, 1 entry
  • “MLN8237 (Alisertib)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.